NeuroOne Medical Technologies (NASDAQ:NMTC) Insider Buys $670,000.00 in Stock

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) insider David Wambeke purchased 1,000,000 shares of the company’s stock in a transaction that occurred on Sunday, March 1st. The shares were acquired at an average cost of $0.67 per share, for a total transaction of $670,000.00. Following the completion of the transaction, the insider directly owned 1,000,000 shares of the company’s stock, valued at $670,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

NeuroOne Medical Technologies Stock Up 5.4%

NeuroOne Medical Technologies stock opened at $0.83 on Friday. The stock has a market cap of $42.07 million, a P/E ratio of -4.90 and a beta of 0.74. NeuroOne Medical Technologies Corporation has a 12 month low of $0.40 and a 12 month high of $1.16. The company’s fifty day simple moving average is $0.81 and its 200-day simple moving average is $0.79.

NeuroOne Medical Technologies (NASDAQ:NMTC) last announced its quarterly earnings results on Tuesday, February 17th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.01. The company had revenue of $2.89 million for the quarter, compared to analyst estimates of $2.47 million. NeuroOne Medical Technologies had a negative net margin of 78.34% and a negative return on equity of 119.92%.

Analyst Ratings Changes

A number of research firms recently issued reports on NMTC. Wall Street Zen upgraded NeuroOne Medical Technologies to a “sell” rating in a research note on Saturday, February 21st. Zacks Research upgraded NeuroOne Medical Technologies from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. Finally, JonesTrading assumed coverage on shares of NeuroOne Medical Technologies in a research note on Monday. They issued a “buy” rating and a $1.50 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, NeuroOne Medical Technologies presently has an average rating of “Moderate Buy” and an average price target of $1.98.

Institutional Trading of NeuroOne Medical Technologies

Large investors have recently added to or reduced their stakes in the company. Warberg Asset Management LLC acquired a new stake in NeuroOne Medical Technologies during the 2nd quarter valued at $27,000. Focus Financial Network Inc. bought a new stake in shares of NeuroOne Medical Technologies during the third quarter worth $31,000. Legato Capital Management LLC acquired a new stake in shares of NeuroOne Medical Technologies in the fourth quarter valued at $34,000. Squarepoint Ops LLC bought a new position in shares of NeuroOne Medical Technologies in the fourth quarter valued at about $36,000. Finally, Susquehanna International Group LLP acquired a new position in NeuroOne Medical Technologies during the 3rd quarter worth about $47,000. 16.07% of the stock is owned by institutional investors.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.